CT Chest, Abdomen, and Pelvis for Malignancy Screening: Contrast Recommendations

Standard Protocol for Malignancy Screening

The American College of Radiology recommends contrast-enhanced CT for cancer screening because it allows improved discrimination of tumor from adjacent tissues, better characterization of focal lesions, and detection of vascular involvement 2
The typical protocol involves 55-100 mL of iodinated contrast at 2-3 mL/s injection rate, with imaging in the portal venous phase (50-60 seconds post-injection) 2
For comprehensive malignancy screening, CT chest, abdomen, and pelvis with contrast provides structural details necessary to guide biopsy and surgical intervention if malignancy is detected 1

The American College of Radiology notes that hypervascular metastases to liver, pancreas, or other organs may only be detected on arterial phase imaging with contrast 4
Pleural malignancies require contrast to distinguish tumor from adjacent chest wall, complex fluid, and atelectatic lung 2
Lymph node characterization is substantially impaired without contrast enhancement 2

For patients with contrast allergy, FDG-PET/CT can serve as the primary screening modality when iodinated contrast is contraindicated, providing functional imaging without requiring IV contrast for the CT component 1
MRI with hepatobiliary contrast agents offers superior soft tissue characterization compared to non-contrast CT, particularly for liver lesions 6

The European Journal of Nuclear Medicine and Molecular Imaging recommends ensuring adequate volume expansion before and after contrast administration to minimize nephrotoxicity risk 8
Measuring serum creatinine and eGFR before any contrast-enhanced study in at-risk patients is recommended 8